LEQEMBI IQLIK
Clinical safety rating
cautionComprehensive clinical and safety monograph for LEQEMBI IQLIK (LEQEMBI IQLIK).
Comprehensive clinical and safety monograph for LEQEMBI IQLIK (LEQEMBI IQLIK).
Alzheimer disease, treatment (early symptomatic)
Monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
| Metabolism | Degraded into small peptides and amino acids via general protein catabolism; no CYP enzyme involvement. |
| Excretion | Primarily proteolytic catabolism to amino acids; renal elimination of intact drug is negligible (<1%). Biliary/fecal excretion is not a major route. |
| Half-life | Terminal half-life approximately 24.6 days (range 23-27 days) in patients with Alzheimer's disease; supports monthly intravenous dosing. |
| Protein binding | Approximately 90% bound to plasma proteins (primarily albumin and immunoglobulins). |
| Volume of Distribution | Approximately 0.07 L/kg (central volume); limited to plasma and interstitial fluid, consistent with large monoclonal antibody. |
| Bioavailability | Not applicable; administered intravenously with 100% bioavailability. Subcutaneous or intramuscular routes not approved. |
| Onset of Action | IV infusion: Clinical effects on amyloid beta plaque reduction observed within 3 months; cognitive benefit typically assessed at 6-12 months. |
| Duration of Action | Sustained amyloid reduction lasting up to 12-18 months after treatment cessation; clinical effects persist for months after last dose. |
| Molecular Weight | Approximately 150,000 Da |
Lecanemab (LEQEMBI IQLIK) for Alzheimer disease: 10 mg/kg IV infusion every 2 weeks, diluted in 250 mL saline, administered over approximately 1 hour. Initiate with 1 mg/kg IV on day 0 and 3 mg/kg IV on day 14 for titration, then 10 mg/kg IV every 2 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment; insufficient data for severe renal impairment (eGFR <30 mL/min/1.73 m²) — use with caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A); not studied in moderate or severe hepatic impairment (Child-Pugh B or C) — use only if benefit outweighs risk. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years); no dose recommendations available. |
| Geriatric use | No specific dose adjustment required for elderly patients based on age alone; consider renal function (eGFR) and overall health status; monitor for infusion-related reactions and amyloid-related imaging abnormalities (ARIA). |
| 1st trimester | No adequate human data; animal studies not available. Use only if potential benefit justifies potential risk to fetus. |
| 2nd trimester | No adequate human data; animal studies not available. Use only if potential benefit justifies potential risk to fetus. |
| 3rd trimester | No adequate human data; animal studies not available. Use only if potential benefit justifies potential risk to fetus. |
Clinical note
Comprehensive clinical and safety monograph for LEQEMBI IQLIK (LEQEMBI IQLIK).
| Placental transfer | Lecanemab is a humanized IgG1 monoclonal antibody; IgG antibodies are known to cross the placenta, with transfer increasing as pregnancy progresses. Extent of transfer for lecanemab is unknown. |
| Breastfeeding | It is unknown whether lecanemab is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, patients should either discontinue breastfeeding or discontinue the drug, considering importance of drug to mother. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No human data available; animal studies show developmental toxicity including reduced fetal weight and skeletal variations at doses below clinical exposure. In first trimester, risk cannot be excluded. Second and third trimester: potential for fetal harm unknown. Monoclonal antibodies cross placenta increasingly after 20 weeks gestation. |
| Fetal Monitoring | Monitor for infusion reactions (hypotension, hypoxia); perform baseline and periodic liver function tests. Assess for amyloid-related imaging abnormalities (ARIA) with MRI if neurological symptoms emerge. Fetal monitoring: consider serial ultrasound for growth and amniotic fluid volume if used during second/third trimester. |
| Fertility Effects | No human fertility data. In animal studies, no adverse effects on male or female fertility at doses up to 300 mg/kg every 2 weeks (AUC exposure 11 times the clinical exposure). |
■ FDA Black Box Warning
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which can be fatal.
| Serious Effects |
Hypersensitivity to lecanemab or any excipients
| Precautions | Amyloid-related imaging abnormalities (ARIA), infusion-related reactions, hypersensitivity reactions, and risk of symptomatic ARIA requiring monitoring via MRI. |
| Food/Dietary | No clinically significant food interactions. Grapefruit juice does not affect lecanemab. Avoid alcohol as it may increase risk of falls and confusion. |
| Clinical Pearls | LEQEMBI IQLIK (lecanemab-irmb) is an amyloid beta-directed monoclonal antibody for Alzheimer disease. Confirm amyloid pathology before initiation. Administer as a 1-hour IV infusion every 2 weeks diluted in 250 mL 0.9% NaCl. Do not administer if infusion-related reactions occur; premedicate with antihistamines, acetaminophen, or corticosteroids. MRI monitoring required prior to doses 5, 7, and 14; suspend if amyloid-related imaging abnormalities (ARIA) with large or multiple hemorrhages occur. Contraindicated in patients on anticoagulants except low-dose aspirin. Dose adjustments not required for age, sex, or renal impairment. Avoid concomitant use with antithrombotic agents due to increased bleeding risk. |
| Patient Advice | This medication treats early Alzheimer disease by reducing amyloid plaques in the brain. · You will receive an intravenous infusion every 2 weeks over 1 hour. · MRI scans of the brain are needed before treatment and at specific doses to monitor for swelling or bleeding. · Common side effects include infusion reactions (fever, chills, rash), headache, and ARIA (headache, confusion, vision changes). · Seek immediate medical attention if you experience severe headache, vision changes, confusion, seizures, or bleeding. · Do not take blood thinners (e.g., warfarin, rivaroxaban, apixaban, dabigatran, edoxaban) unless prescribed low-dose aspirin. · Inform your doctor of all medications, including over-the-counter and herbal supplements. · Genetic testing for APOE4 status may be recommended to assess ARIA risk. |
Loading safety data…